IMPAACT 2010 Update: Comparable Safety and Efficacy With DTG + FTC/TAF or FTC/TDF vs EFV/FTC/TDF at 50 Wks Postpartum Following Initiation in Pregnancy

March 6-10, 2021; Virtual

In this randomized noninferiority trial, the overall safety and efficacy of DTG plus FTC/TAF or FTC/TDF was generally similar to EFV/FTC/TDF when initiated during pregnancy, but in post hoc analyses, infant mortality, virologic failure at ≥ 24 weeks, and maternal weight loss were all higher with EFV/FTC/TDF vs DTG-based regimens.

Format: Microsoft PowerPoint (.ppt)
File Size: 176 KB
Released: March 11, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Clinical Care Options (CCO) expert analysis of new HIV data from IDWeek 2021, provided by expert HIV faculty

Eric S. Daar, MD Released: October 21, 2021

Clinical Care Options (CCO) expert analysis of new HIV data from IDWeek 2021, provided by expert HIV faculty

Darcy Wooten, MD Released: October 20, 2021

Slides from CCO: ART in Pregnancy: guideline recommendations and supporting data, pharmacokinetic considerations, and drug-drug interactions

person default Milena Murray, PharmD, MSc, BCIDP, AAHIVP Jonah Musa, MBBS, MSCI, PhD Released: October 20, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue